Horizon Technology Finance (NASDAQ:HRZN) Posts Earnings Results, Misses Estimates By $0.13 EPS

05 May 2026, 21:32 by Doug Wharley · The Cerbat Gem

Horizon Technology Finance (NASDAQ:HRZN – Get Free Report) posted its quarterly earnings results on Tuesday. The investment management company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.13), FiscalAI reports. Horizon Technology Finance had a positive return on equity of 14.52% and a negative net margin of 2.77%.The firm had revenue of ($6.19) million for the quarter, compared to the consensus estimate of $21.09 million.

Horizon Technology Finance Stock Performance

HRZN stock traded up $0.05 during trading on Tuesday, reaching $4.23. 957,592 shares of the company traded hands, compared to its average volume of 1,027,721. Horizon Technology Finance has a 12 month low of $3.80 and a 12 month high of $8.46. The business has a 50 day simple moving average of $4.55 and a 200 day simple moving average of $5.82. The company has a market capitalization of $202.24 million, a price-to-earnings ratio of -26.44 and a beta of 0.99.

Horizon Technology Finance Dividend Announcement

The business also recently disclosed a monthly dividend, which will be paid on Tuesday, June 16th. Investors of record on Monday, May 18th will be given a dividend of $0.06 per share. The ex-dividend date of this dividend is Monday, May 18th. This represents a c) dividend on an annualized basis and a yield of 17.0%. Horizon Technology Finance’s dividend payout ratio (DPR) is presently -450.00%.

Institutional Investors Weigh In On Horizon Technology Finance

A number of institutional investors have recently added to or reduced their stakes in the stock. Eagle Point Credit Management LLC bought a new stake in Horizon Technology Finance during the fourth quarter valued at about $2,385,000. Millennium Management LLC acquired a new stake in Horizon Technology Finance in the third quarter worth about $1,099,000. UBS Group AG boosted its holdings in Horizon Technology Finance by 40.3% in the third quarter. UBS Group AG now owns 106,964 shares of the investment management company’s stock worth $652,000 after acquiring an additional 30,716 shares in the last quarter. Magnetar Financial LLC acquired a new stake in Horizon Technology Finance in the third quarter worth about $435,000. Finally, Aquatic Capital Management LLC acquired a new stake in Horizon Technology Finance in the third quarter worth about $395,000. Institutional investors own 4.94% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HRZN. Keefe, Bruyette & Woods raised Horizon Technology Finance from an “underperform” rating to a “market perform” rating and set a $5.00 price target on the stock in a research report on Thursday, March 5th. Oppenheimer dropped their price target on Horizon Technology Finance from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Tuesday, March 24th. Weiss Ratings reissued a “sell (d)” rating on shares of Horizon Technology Finance in a research report on Thursday, January 22nd. B. Riley Financial dropped their price target on Horizon Technology Finance from $7.00 to $5.50 and set a “neutral” rating on the stock in a research report on Friday, March 6th. Finally, Wall Street Zen downgraded Horizon Technology Finance from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $6.10.

View Our Latest Stock Report on Horizon Technology Finance

Horizon Technology Finance Company Profile

(Get Free Report)

Horizon Technology Finance Corporation is a specialty finance company organized as a business development company (BDC) that provides private credit solutions to venture capital and private equity-backed technology, life science and healthcare companies. The firm targets companies at various stages of development, offering secured debt financing structures such as first‐lien and second‐lien loans, as well as equity co‐investment opportunities in select portfolio companies.